At Epi One, our board of directors is more than a governance body. It is a powerhouse of experience, innovation, and mission-driven leadership.
Each member brings a unique blend of expertise across science, technology, healthcare, and business, creating a collaborative environment where strategy and purpose align. Together, the board helps guide Epi One’s vision of transforming cancer detection, ensuring that every decision balances scientific rigor with the practicalities of scaling impact.
Among this distinguished group, Daniel Etra stands out as a leader whose entrepreneurial success and deep healthcare technology background make him an invaluable asset to the company’s mission.
Daniel brings nearly three decades of international business leadership, strategic acumen, and entrepreneurial spirit to the boardroom. As an accomplished founder, operator, and tech-savvy healthcare innovator, his track record uniquely positions him to help steer Epi One toward our ambitious goal of transforming cancer detection.
Background
A Yale University alumnus with a BA in Economics, Daniel advanced to earn his MBA from Harvard Business School, credentials that laid a strong foundation for his career in both advisory and operational roles.
He began his professional journey in high-stakes environments: supporting M&A transactions in healthcare, tech, and natural resources at Wasserstein Perella & Co. and later as a consultant at Bain & Company, helping to launch their New York office. Previously he served as Managing Director of Promodex Ltd., steering the family-run importer/distributor to a successful sale, and later co-founded and led R.E.R. International LLC, a retail supply chain enterprise, through another successful exit.
Daniel’s entrepreneurial momentum continued with the founding of RethinkFirst, a global behavioral‑health technology venture. Under his leadership, Rethink evolved into a market-leading platform delivering evidence-based, ABA-informed treatment tools, training and data analytics through scalable, cloud-based solutions. These resources serve public school systems, Fortune 500 employers, government agencies including the U.S. Department of Defense, managed‑care organizations, and families, reaching millions of users across over 100 countries.
Daniel’s impact is underscored by industry recognition: under his direction, Rethink garnered numerous awards, such as Healthcare AI Excellence Award, Inc. 500, Interactive Media Awards, and honors in inclusive education and behavioral‑health innovation. He also earned individual accolades like CEO of the Year and the SmartCEO Future 50 Award.
Impact
Beyond his impressive business credentials, Daniel brings to Epi One a rare combination of strategy, operational excellence, and mission-driven leadership. His founding of Rethink showcases how he leverages technology to fill critical gaps in healthcare and education by scaling best-practice clinical tools globally. This resonates with Epi One’s mission to innovate in cancer detection, where adopting scalable, tech‑enabled solutions can have game-changing impact.
Since joining Epi One’s board in 2023, Daniel has contributed more than just leadership. His ability to navigate growth phases, drive integration of science and business, and sharpen strategic direction is invaluable, and his understanding of cross-functional collaboration, data-driven tools, and stakeholder ecosystems is critical to advancing Epi One’s vision of early detection and meaningful healthcare transformation.
As we chart our path toward transforming early cancer detection, Daniel’s leadership ensures the company stays mission-aligned, operationally sound, and impactful on a global scale.
